GB0307262D0 - Use of fluoroquinolone antibiotics for the treatment of q fever - Google Patents

Use of fluoroquinolone antibiotics for the treatment of q fever

Info

Publication number
GB0307262D0
GB0307262D0 GBGB0307262.6A GB0307262A GB0307262D0 GB 0307262 D0 GB0307262 D0 GB 0307262D0 GB 0307262 A GB0307262 A GB 0307262A GB 0307262 D0 GB0307262 D0 GB 0307262D0
Authority
GB
United Kingdom
Prior art keywords
fever
treatment
fluoroquinolone antibiotics
fluoroquinolone
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0307262.6A
Other versions
GB2400033A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Priority to GB0307262A priority Critical patent/GB2400033A/en
Publication of GB0307262D0 publication Critical patent/GB0307262D0/en
Publication of GB2400033A publication Critical patent/GB2400033A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0307262A 2003-03-29 2003-03-29 Use of fluoroquinolone antibiotics for the treatment of Q fever Withdrawn GB2400033A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0307262A GB2400033A (en) 2003-03-29 2003-03-29 Use of fluoroquinolone antibiotics for the treatment of Q fever

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0307262A GB2400033A (en) 2003-03-29 2003-03-29 Use of fluoroquinolone antibiotics for the treatment of Q fever

Publications (2)

Publication Number Publication Date
GB0307262D0 true GB0307262D0 (en) 2003-05-07
GB2400033A GB2400033A (en) 2004-10-06

Family

ID=9955780

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0307262A Withdrawn GB2400033A (en) 2003-03-29 2003-03-29 Use of fluoroquinolone antibiotics for the treatment of Q fever

Country Status (1)

Country Link
GB (1) GB2400033A (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI287987B (en) * 2000-08-14 2007-10-11 Senju Pharma Co Cytokine inhibitor

Also Published As

Publication number Publication date
GB2400033A (en) 2004-10-06

Similar Documents

Publication Publication Date Title
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
GB0307918D0 (en) Therapeutic use
HUS2200036I1 (en) Use of dihydroimidazolones for the treatment of dogs
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
HK1098687A1 (en) Novel use of quinolone antibiotics
IL178827A0 (en) Use of reboxetine for the treatment of pain
GB0329874D0 (en) Compounds useful for the treatment of diseases
GB0305150D0 (en) Use of therapeutic compounds
PT1487828E (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
IL160143A0 (en) Novel imidazopyridine compounds with therapeutic effect
EP1626692A4 (en) Compounds for the treatment of flaviviridae infections
GB0306604D0 (en) Second medical use
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1622615A4 (en) Naphthyridine integrase inhibitors
PL371524A1 (en) Combination therapy for the treatment of bacterial infections
EP1827449A4 (en) The use of novel antibacterial compounds
LT1496918T (en) Use of sodium meta-arsenite for the treatment of tumours
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
GB0415181D0 (en) Compounds for use in the treatment of infection
ZA200509590B (en) Nitrogen-containing heteroaryl derivatives for the treatment of HCV-infection
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
GB0307262D0 (en) Use of fluoroquinolone antibiotics for the treatment of q fever
PL377902A1 (en) Novel use of phosphor-nitrogen-metal complex
HK1087027A1 (en) Use of 2H-Ä1, 3Ü-oxazinoÄ3,2-AÜindole derivatives for the treatment of neuropathic pain
IL170706A0 (en) Use of atii antagonist for the treatment or prevention of metabolic syndrome

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)